Comparable stake leader
Plambeck Jeremy Myung Jae
SEC ownership of BriaCell Therapeutics Corp.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001610820.
Disclosed value leader
Marc Lustig
Comparable rows
5/37
Latest evidence
30 Jun 2026
- Public ticker
- BCTX, BCTXL, BCTXZ on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Plambeck Jeremy Myung Jae
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
5 of 37
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Plambeck Jeremy Myung Jae
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001610820
- Issuer location
- West Vancouver, British Columbia, Canada
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BriaCell Therapeutics Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Plambeck Jeremy Myung Jae
Disclosed value leader
Marc Lustig
Comparable rows
5/37
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 100%
32 rows are not safely comparable across share classes.
13D/G row: Plambeck Jeremy Myung Jae
Showing 1-8 of 37 holder rows.
Quick read
Plambeck Jeremy Myung Jae leads the comparable SEC ownership view at 100%.
5 of 37 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Plambeck Jeremy Myung Jae's linked filing trail.
Comparable ownership
Top 5
Plambeck Jeremy Myung Jae
100%
CITADEL ADVISORS LLC
10%
Iroquois Capital Management, LLC
9.1%
CVI Investments, Inc.
4.9%
3i, LP
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 37 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Plambeck Jeremy Myung Jae |
13D/G
|
100%
Reported 13D/G
· 25 Aug 2025
|
—
13,339 shares
|
$0 | 25 Aug 2025 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
10%
Reported 13D/G
· 15 Jan 2026
|
$5,119,574
717,198 shares
|
$0 | 15 Jan 2026 |
| Iroquois Capital Management, LLC |
13D/G
Richard Abbe
|
9.1%
Reported 13D/G
· 15 Jul 2025
|
$4,736,000
1,600,000 shares
|
$0 | 15 Jul 2025 |
| CVI Investments, Inc. |
13D/G
|
4.9%
Reported 13D/G
· 30 Sep 2025
|
$1,088,384
98,944 shares
|
$0 | 30 Sep 2025 |
| 3i, LP |
13D/G
|
4.9%
Reported 13D/G
· 31 Mar 2025
|
$872,128
190,006 shares
|
-$821,582 | 31 Mar 2025 |
| Marc Lustig |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$5,632,601
3,445,870 shares
mixed-class rows
|
— | 14 May 2024 |
| Cable Car Capital, LP |
13F
Company
|
—
mixed-class rows
|
$988,989
538,719 shares
mixed-class rows
|
— | 30 Jun 2026 |
| Jamieson Bondarenko |
3/4/5
Chairman, Director
|
—
denominator unverified
|
$777,940
169,856 shares
|
— | 28 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 21 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to BriaCell Therapeutics Corp.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Marc Lustig
Net 12M change
$0
Latest report
14 May 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Marc Lustig | Director, 10%+ Owner | $5,632,601 | Filing P/S | 14 May 2024 | ||
| Jamieson Bondarenko | Chairman, Director | $777,940 | Filing P/S | 28 Dec 2022 | ||
| William V Williams | President, CEO, Director | $57,816 | Filing P/S | 23 Dec 2022 | ||
| Vaughn C. Embro-Pantalony | Director | $43,620 | Mixed | 01 Aug 2022 | ||
| Gadi Levin | CFO & Secretary | $12,870 | Mixed | 01 Aug 2022 | ||
| Martin E. Schmieg | Director | $2,634 | Mixed | 01 Aug 2022 | ||
| Rebecca Taub | Director | Mixed | 01 Aug 2022 | |||
| Giuseppe del Priore | Chief Medical Officer | Mixed | 01 Aug 2022 | |||
| Jane A. Gross | Director | Mixed | 01 Aug 2022 | |||
| Miguel A. Lopez-Lago | Chief Scientific Officer | Mixed | 01 Aug 2022 |
Recent insider transactions for BriaCell Therapeutics Corp.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.